Merileijona
Merileijona is a Finnish term referring to a subset of the Lewy body dementia (LBD) spectrum, specifically characterized by alpha-synuclein pathology and distinct clinical features. The condition is named after the Finnish psychiatrist and neurologist, Erkki Meri, who first described it in the early 21st century.
Individuals diagnosed with Merileijona typically exhibit rapid progression of cognitive decline, often accompanied by fluctuations in
Imaging and biomarker analyses, including positron emission tomography (PET) with dopamine transporter (DaT) ligands, can help
Treatment for Merileijona mostly involves managing symptoms through medication and non-pharmacological interventions. These treatments help alleviate
One key aspect of distinct Merileijona clinical profiles is an abnormal presence of sleepiness. Quantitative evaluation